New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
12:10 EDTESRX, ENOC, OMX, SREV, NYX, ODP, WTW, CVC, AOLOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as Americans headed to the polls. Stock futures improved during the premarket trading session, leading to a slightly higher open for the broader market. The averages slowly gained upside momentum and eventually punched through for their best gains in a couple of weeks. The domestic economic calendar was quiet and investors may be factoring an end to the presidential election process, along with hope that political leaders will get back to work on the country’s problems, as the catalyst for the buying... ECONOMIC EVENTS: In the U.S., the Job Openings and Labor Turnover survey, or JOLTs report, showed job openings fell 100K to 3.56M in September from 3.66M in August. In Europe, a report showed that the shared currency area's business activity shrank in October at its steepest rate in over three years. In Germany in particular, which is the region's biggest economy, the composite services and manufacturing purchasing managers index came in at 48.4, below the consensus forecast of 49.3, and factory orders for the month of September were weaker than expected as well... COMPANY NEWS: Among companies reporting earning last night and this morning, AOL (AOL), Office Depot (ODP) and OfficeMax (OMX) advanced, while Cablevision (CVC) and NYSE Euronext (NYX) declined... MAJOR MOVERS: Among the notable gainers were EnerNOC (ENOC), up 21% following price target raises at RW Baird and Needham after its Q3 results, and Weight Watchers (WTW), up over 16% after its quarterly earnings beat expectations. Among the noteworthy losers was ServiceSource (SREV), down 35% amid at least three downgrades after the company lowered its revenue growth view for the upcoming quarter and the fiscal year. Also lower were shares of Express Scripts (ESRX), down 13% after saying that it views current consensus estimates for 2013 as "overly aggressive" and disclosing that its Accredo Health unit received a subpoena from the Department of Justice... INDICES: Near noon, the Dow was up 171.63, or 1.31%, to 13,284.07; the Nasdaq was up 21.82, or 0.73%, to 3,021.48; and the S&P 500 was up 14.96, or 1.06%, to 1,432.22.
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
07:20 EDTESRXJPMorgan positive on Express Scripts after management meetings
Subscribe for More Information
November 24, 2015
11:50 EDTENOCEnerNOC management to meet with Needham
Subscribe for More Information
November 23, 2015
08:08 EDTESRXBarron's article on Express Scripts a mischaracterization, says JPMorgan
Subscribe for More Information
November 22, 2015
13:11 EDTESRXExpress Scripts' link to specialty drug makers presents new risk, Barron's says
Express Scripts' (ESRX) United BioSource unit -- often hired by specialty drug makers to help patients find money for costly treatments -- appears at odds with the company's role in negotiating lower drug prices, Barron's contends in a feature article. Though Express Scripts will continue to earn the "vast majority" of its profits as a pharmacy-benefit manager, Barron's argues that investors should view its work on behalf of specialty drug companies as a risk factor for the stock, particularly in light of recent Valeant (VRX) and Horizon (HZNP) headlines. Reference Link
November 20, 2015
18:58 EDTESRXExpress Scripts management to meet with JPMorgan
Meeting to be held in New York on November 24 hosted by JPMorgan.
November 19, 2015
06:19 EDTODPFTC looking over Staples, Office Depot transaction, NY Post reports
Subscribe for More Information
November 18, 2015
15:40 EDTESRXCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
November 17, 2015
10:17 EDTESRXHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
07:52 EDTWTWMorgan Stanley to hold a conference
Subscribe for More Information
November 16, 2015
09:06 EDTESRXDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
06:18 EDTESRXDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
06:16 EDTCVCAltice targeting NYC internet expansion for Cablevision, NY Post reports
Altice (ATCEY), which sees its takeover of Cablevision (CVC) closing next year, is in discussions over expanding the cable company's fiber optic network to tis 3.1M customers in the New York City area, the New York Post reports. Altice has held talks with the New York City Department of Information Technology and the Public Service Commission, noting the company's progress in developing high-speed service in France and Portugal, the report says. Reference Link
05:37 EDTWTWStocks with implied volatility below IV index mean; MW WTW
Subscribe for More Information
05:30 EDTODPStocks with implied volatility above IV index mean; ODP CRM
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use